Model NO.:

QS-Montelukast Sodium

CAS No.:

151767-02-1

Formula:

C35h35clnnao3s

EINECS:

604-813-7

Packaging Material:

Negotiable

Storage Method:

Normal

Shelf Life:

>12 Months

Nutrient Composition:

Montelukast Sodium

Resource:

Montelukast Sodium

The content of active substances:

>99%

Product Name:

Montelukast Sodium

Name:

Montelukast Sodium Powder

Appearance:

White Powder

Colour:

White

Grade:

Pharmaceutical Grade

Assay:

>99%

Application:

Pharmaceutical

Specific:

COA

Test Method:

HPLC

Mf:

C35h35clnnao3s

MW:

608.169

Refractive Index:

1.538

Boiling Point:

760mmhg

Storage Tempera:

2-8c

Melting Point:

84-90c

Trademark:

QS-Montelukast Sodium

Transport Package:

Negotiable

Specification:

>99%

Origin:

Xi`an

Product Description

Antiasthmatic CAS151767-02-1 Montelukast sodium Powder Montelukast sodium

Product name	Montelukast Sodium
Cas number	151767-02-1
Appearance	White powder
MF	C35H35ClNNaO3S
MW	608.169

Montelukast Sodium is a highly potent and selective antagonist of the CysLT1 receptor (with an IC50 of less than 5 nM), exhibiting no significant effect on the CysLT2 receptor. It functions by competitively inhibiting leukotrienes, particularly LTD4, a key mediator involved in pulmonary and immune system pathways. In studies on rat colitis, Montelukast Sodium has been shown to enhance PGE2 (Prostaglandin E2) production while reducing COX-2 expression. Due to its specific mechanism of action, it is not effective for treating acute asthma attacks but is suitable for long-term management. Additionally, it does not interfere with other asthma medications like theophylline. Another drug in the same class is zafirlukast (Accolate), which also targets leukotriene receptors.

Montelukast is a potent oral leukotriene receptor antagonist that effectively improves asthma inflammation by inhibiting leukotrienes, which are released during inflammatory responses like allergen exposure. It selectively targets type I cysteinyl leukotriene receptors (CysLT1), blocking the effects of inflammatory mediators (LTC4, LTD4, LTE4) without agonist activity. Clinically, it is used for the prevention and long-term treatment of asthma in patients aged 15 and older, including daytime and nighttime symptoms, aspirin-sensitive asthma, and exercise-induced bronchoconstriction. It also alleviates symptoms of seasonal allergic rhinitis, such as sneezing, nasal congestion, runny nose, and itching.

Message Type
* Message Content
* Name
* Phone
* Email
* CAPTCHA

Antiasthmatic CAS151767-02-1 Montelukast Sodium Powder Montelukast Sodium

Xi'an Qiushi Co., Ltd.